epicombi.ai

Targeting epigenetically induced tumour loss of identity and immune masking with AI-discovered, network-acting drugs

General Information
Company Name
epicombi.ai
Founded Year
2017
Location (Offices)
Oxford, United Kingdom +1
Founders / Decision Makers
Number of Employees
2-10
Industries
AI, Biotechnology, Machine Learning
Funding Stage
Seed
Social Media

epicombi.ai - Company Profile

EpiCombi.AI is a seed stage biotechnology company focused on the use of Machine Learning to power a new type of drug discovery workflow applied initially to Cancer but more broadly to other disease conditions based in Oxford, United Kingdom.

Taxonomy: AI-driven drug discovery, Cancer therapeutics, Genomics signature analysis, Machine Learning in healthcare, Epigenetics, Network-acting drugs, Multi-targeted drugs, Oxford spinout, Tumour identity loss, Immune masking, Cancer complexity, Genomics, Therapeutics, Seed stage startup

Funding Rounds & Investors of epicombi.ai (0)

View All

There is no investment information

Latest News of epicombi.ai

View All

No recent news or press coverage available for epicombi.ai.

Similar Companies to epicombi.ai

View All
858 Therapeutics - Similar company to epicombi.ai
858 Therapeutics Discovering innovative small molecule therapeutics for the treatment of cancer
Galera Therapeutics, Inc. - Similar company to epicombi.ai
Galera Therapeutics, Inc. Transforming the science and treatment of cancer
EPICS Therapeutics - Similar company to epicombi.ai
EPICS Therapeutics EPICS is a drug discovery and development company for small molecule drugs targeting RNA epigenetic mecanisms of cancer
Calithera Biosciences - Similar company to epicombi.ai
Calithera Biosciences Targeting cancer, differently.
Lytix Biopharma - Similar company to epicombi.ai
Lytix Biopharma A clinical-stage immuno-oncology company developing proprietary oncolytic drugs as a novel therapy to fight cancer.